Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
University of North Carolina, Chapel Hill, North Carolina Kenya
Moi University Clinical Research Center, Eldoret Kenya Medical Research Institute/Walter Reed Project, Kericho